We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Read MoreHide Full Article
Key Takeaways
Stryker shares rose 13.6% in three months as Q2 organic sales grew 9% and adjusted EPS climbed 17.9%.
SYK faces production, vascular backlog and cyber-cost pressures as it works to sustain second-half momentum.
Stryker trades at 21.6X forward earnings, above the sub-industry's 17.5X but below its five-year median.
Stryker Corporation (SYK - Free Report) shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector’s 12.9% gain and the S&P 500’s 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter.
The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.
Image Source: Zacks Investment Research
Why Stryker’s Three-Month Rally Has Support
Stryker’s second-quarter results gave investors firmer operating evidence. Organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share. Management said the company exited the quarter with regained momentum after the March cybersecurity disruption.
Demand remained broad across the portfolio. MedSurg and Neurotechnology organic sales increased 9.2%, while Orthopaedics rose 8.6%. That breadth matters because the recovery is not resting on one product line or a single procedural category.
Stryker’s Q2 Recovery Reset the Narrative
Capital equipment was a major contributor as production came back online, and Stryker ended the quarter with elevated backlog and strong orders. Mako also posted its best-ever second quarter for installations in both the United States and international markets, with utilization continuing to rise.
The competitive backdrop remains active. Zimmer Biomet Holdings, Inc. (ZBH - Free Report) reported 4% organic constant-currency sales growth in its latest quarter and is advancing its ROSA robotic platform. Intuitive Surgical, Inc. (ISRG - Free Report) reported 16% growth in combined da Vinci and Ion procedures and placed 468 da Vinci systems, underscoring continued demand for robotic-assisted care.
SYK Still Faces Execution Tests in the Second Half
The recovery is not complete. Management still needs to ramp production fast enough to convert a large capital order book, while U.S. Peripheral Vascular back orders are expected to fall to a manageable level by the end of the third quarter.
Costs remain another watch point. Cyber remediation and stabilization spending will continue through the year, while manufacturing and supply-chain costs were roughly a 100-basis-point first-half gross-margin headwind. Those pressures could affect delivery timing and operating leverage if recovery work takes longer than planned.
Valuation Could Cap Stryker’s Next Leg Higher
After the rally, Stryker trades at 21.6X forward 12-month earnings. That is above the Zacks sub-industry’s 17.5X multiple, suggesting investors are already paying a premium for Stryker’s growth profile and recovery prospects.
The signal is not uniformly expensive, however. SYK remains below its own five-year median of 26X. That leaves valuation in a middle ground: richer than peers, but still below the stock’s longer-term norm.
Image Source: Zacks Investment Research
Wrapping Up
Stryker’s operating case has improved, but the next phase depends on execution. Production recovery, vascular backlog reduction and continued earnings momentum need to hold up against lingering remediation and manufacturing costs.
Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. The investment decision is better anchored to valuation, second-half execution and the durability of earnings growth rather than assuming the recent rally will continue.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Key Takeaways
Stryker Corporation (SYK - Free Report) shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector’s 12.9% gain and the S&P 500’s 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter.
The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.
Image Source: Zacks Investment Research
Why Stryker’s Three-Month Rally Has Support
Stryker’s second-quarter results gave investors firmer operating evidence. Organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share. Management said the company exited the quarter with regained momentum after the March cybersecurity disruption.
Demand remained broad across the portfolio. MedSurg and Neurotechnology organic sales increased 9.2%, while Orthopaedics rose 8.6%. That breadth matters because the recovery is not resting on one product line or a single procedural category.
Stryker’s Q2 Recovery Reset the Narrative
Capital equipment was a major contributor as production came back online, and Stryker ended the quarter with elevated backlog and strong orders. Mako also posted its best-ever second quarter for installations in both the United States and international markets, with utilization continuing to rise.
The competitive backdrop remains active. Zimmer Biomet Holdings, Inc. (ZBH - Free Report) reported 4% organic constant-currency sales growth in its latest quarter and is advancing its ROSA robotic platform. Intuitive Surgical, Inc. (ISRG - Free Report) reported 16% growth in combined da Vinci and Ion procedures and placed 468 da Vinci systems, underscoring continued demand for robotic-assisted care.
SYK Still Faces Execution Tests in the Second Half
The recovery is not complete. Management still needs to ramp production fast enough to convert a large capital order book, while U.S. Peripheral Vascular back orders are expected to fall to a manageable level by the end of the third quarter.
Costs remain another watch point. Cyber remediation and stabilization spending will continue through the year, while manufacturing and supply-chain costs were roughly a 100-basis-point first-half gross-margin headwind. Those pressures could affect delivery timing and operating leverage if recovery work takes longer than planned.
Valuation Could Cap Stryker’s Next Leg Higher
After the rally, Stryker trades at 21.6X forward 12-month earnings. That is above the Zacks sub-industry’s 17.5X multiple, suggesting investors are already paying a premium for Stryker’s growth profile and recovery prospects.
The signal is not uniformly expensive, however. SYK remains below its own five-year median of 26X. That leaves valuation in a middle ground: richer than peers, but still below the stock’s longer-term norm.
Image Source: Zacks Investment Research
Wrapping Up
Stryker’s operating case has improved, but the next phase depends on execution. Production recovery, vascular backlog reduction and continued earnings momentum need to hold up against lingering remediation and manufacturing costs.
Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. The investment decision is better anchored to valuation, second-half execution and the durability of earnings growth rather than assuming the recent rally will continue.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.